Company intelligence / Profile preview

Sycai Medical

Barcelona, Catalonia, Spainsycaimedical.com ↗

Ownership: Private
Employees: ~5
Development stage: Commercial

Overview

Sycai Medical has successfully completed its first clinical trial in 2023. Its AI-driven software received CE mark under MDR regulations in summer 2024 for pancreatic applications. The company is expanding to include hepatic and renal lesions and is preparing for US FDA approval. The platform enables early diagnosis of cancer/pre-malignant lesions from CT/MRI scans without invasive tests.

Therapeutic areas: OncologyGastroenterology
Modalities: DeviceArtificial intelligence (AI)-based softwareNon-pharmacological therapy (diagnostic tool)
Industry: Digital Health Medical Devices

Beyond the preview

Go deeper on Sycai Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sycai Medical.

Explore the full profile